DiogenX
Renaud Perret is a seasoned finance and administration professional with extensive experience in financial management and reporting, human resources, and administration across various organizations. Currently serving as the Director of Finance & Administration at DiogenX since February 2024, Renaud previously held similar roles at Invectys from February 2019 to January 2024, where responsibilities included oversight of financial operations and compliance with a U.S. parent company. Renaud's background also includes significant positions at GSK Pharmaceuticals France and GSK Consumer Healthcare France, focusing on financial analysis, budgeting, and transformation initiatives. Academic credentials include an Executive Master in Strategy & Management of International Business from ESSEC Business School and a Master in Management of Healthcare Companies from ESC Marseille Business School, in addition to specialized training in the pharmaceutical industry.
This person is not in any teams
DiogenX
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.